Ousavi-Jarrahi A, Ozent k G, Soipova M, Tuncer M, Sobue T: Cancer epidemiology and manage in North-Western and Central Asia – previous, present and future. Asian Pac J Cancer Prev 2010, 11(Supple two):17?2. 3. Hao J, Chen WQ: Chinese cancer registry annual report. Beijing: Military Healthcare Science Press; 2012. 4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993, 72(1):37?1. five. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M: Randomised comparison of f luorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in individuals with non-resectable gastric cancer. Br J Cancer 1995, 71(3):587?91. six. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Upper gastrointestinal clinical studies group of the national cancer study institute on the Uk: capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358(1):36?six. 7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, V325 Study Group: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of your V325 Study Group.4-Tetrahydrothiopyranone 1,1-dioxide site J Clin Oncol 2006, 24(31):4991?997. 8. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE: Chemotherapy in sophisticated gastric cancer: a systematic critique and meta-analysis determined by aggregate information. J Clin Oncol 2006, 24(18):2903?909. 9. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2 constructive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase three, open-label, randomised controlled trial.1,2-Oxathiolane 2,2-dioxide Data Sheet Lancet 2010, 376(9742):687?97. ten. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, et al: Expression of epidermal development aspect receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007, 109(four):658?67. 11. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, H ler H, Sarbia M: Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal development aspect receptor in oesophageal adenocarcinoma: a tissue microarray study.PMID:33487539 J Clin Pathol 2006, 59(six):631?34. 12. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and higher gene copy quantity. Histopathology 2008, 52(6):738?46. 13. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F: Epidermal development element receptor (EGFR) expression is related with a worse prognosis in gastric cancer individuals undergoing curative surgery. World J Surg 2007, 31(7):1458?468. 14. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G: Expression of vascular endothelial development issue (VEGF) and epidermal development aspect receptor (EGFR) is definitely an independent prognostic indicator of worse outcome in gastric cancer sufferers. Ann Surg Oncol 2008, 15(1):69?9. 15. Hsieh AC, Moasser MM: Targeting HER prote.
